1432501-47-7

Basic information

• Product Name: (2R,4R)-5-(3'-chlorobiphenyl-4-yl)-2-hydroxy-4-[(2-phenoxyethoxyoxalyl)amino]pentanoic acid
• Synonyms: (2R,4R)-5-(3'-chlorobiphenyl-4-yl)-2-hydroxy-4-[(2-phenoxyethoxyoxalyl)amino]pentanoic acid
• CAS NO: 1432501-47-7
• Molecular Weight: 511.959
• Mol File: 1432501-47-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2R,4R)-5-(3'-chlorobiphenyl-4-yl)-2-hydroxy-4-[(2-phenoxyethoxyoxalyl)amino]pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4R)-5-(3'-chlorobiphenyl-4-yl)-2-hydroxy-4-[(2-phenoxyethoxyoxalyl)amino]pentanoic acid(1432501-47-7)
• EPA Substance Registry System: (2R,4R)-5-(3'-chlorobiphenyl-4-yl)-2-hydroxy-4-[(2-phenoxyethoxyoxalyl)amino]pentanoic acid(1432501-47-7)

Safety Data

• Hazardous Substances Data: 1432501-47-7(Hazardous Substances Data)

Upstream product

• 122-99-6 2-Phenoxyethanol 
• 1432502-21-0 (2R,4R)-4-amino-5-(3'-chlorobiphenyl-4-yl)-2-hydroxypentanoic acid ethyl ester hydrochloride 
• 1432502-19-6 (3R,5R)-5-(3'-chlorobiphenyl-4-ylmethyl)-1-(2,2-dimethylpropionyl)-3-hydroxypyrrolidin-2-one 
• 1432502-20-9 (2R,4R)-4-amino-5-(3'-chlorobiphenyl-4-yl)-2-hydroxypentanoic acid hydrochloride 
• 1432502-18-5 C₂₂H₂₄ClNO₂ 
• 1432502-17-4 C₁₇H₁₆ClNO 
• 1432502-16-3 C₂₂H₂₄ClNO₃ 
• 1394050-15-7 [(S)-1-(4-bromobenzyl)-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)ethyl]carbamic acid t-butyl ester 
• 1383027-95-9 C₂₀H₂₄BrNO₇ 
• 79561-82-3 (2R)-3-(4-bromophenyl)-2-[[(tert-butoxy)carbonyl]amino]propanoic acid 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 
• 1383028-06-5 (S)-2-(4-bromobenzyl)-5-oxopyrrolidine-1-carboxylic acid tert-butyl ester 
• 1432502-23-2 chlorooxoacetic acid 2-phenoxyethyl ester 
• 1432502-72-1 (2R,4R)-4-amino-5-(3'-chlorobiphenyl-4-yl)-2-hydroxypentanoic acid benzyl ester 

Relevant articles and documents

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.